Adipotide

Also known as: Adipotide, FTPP, Fat-Targeted Proapoptotic Peptide, CKGGRAKDC-GG-D(KLAKLAK)₂

2 notable studies · 3 references

View Supplier Listings Take This Adipotide Study With You

TLDR

Adipotide is an experimental fat-targeting proapoptotic peptidomimetic that reduces white adipose tissue by damaging its supporting vasculature and produced substantial weight loss and improved insulin sensitivity in obese animal models, including rhesus monkeys, but human obesity efficacy is unestablished and primate studies identified renal toxicity as an important safety concern.

 Research Supports Studied for effects on obesity and white adipose tissue via targeted vascular ablation
Investigated for effects on insulin resistance
Examined for effects on visceral and abdominal fat
Studied as a proof-of-concept for targeted vascular-delivery therapy
 

 Observations Reported in Research Caused rapid white-fat loss and reversed obesity-related metabolic abnormalities in mice (Kolonin et al., 2004)
Reduced body weight, BMI, abdominal circumference, and adipose tissue and improved insulin resistance in obese rhesus monkeys (Barnhart et al., 2011)
The same primate study identified reversible renal proximal-tubule dysfunction as a safety signal
 

These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.

At a Glance

Classification: Synthetic targeted proapoptotic peptidomimetic; adipose-vasculature-targeting experimental compound

Adipotide is an experimental compound designed to reduce white adipose tissue through a mechanism completely different from GLP-1 drugs or conventional appetite suppressants. Rather than primarily changing hunger or nutrient signaling, adipotide was designed to target blood vessels supplying white adipose tissue. Its architecture combines: CKGGRAKDC an adipose-vasculature-homing sequence with D(KLAKLAK)₂ a proapoptotic sequence. The targeting portion recognizes prohibitin associated with white-adipose vasculature. The proapoptotic component then damages targeted endothelial cells. The proposed result: adipose vasculature disrupted ↓ fat tissue loses vascular support ↓ white adipose tissue decreases. This produced substantial weight and fat loss in obese mice and later in spontaneously obese rhesus monkeys. But the same primate research also identified an important toxicity signal: renal proximal-tubule dysfunction. Adipotide has not become an established human obesity treatment.

What Is Adipotide?

Adipotide originated from an unusual idea: Instead of directly targeting adipocytes, could researchers identify the blood vessels uniquely associated with white fat and destroy those? Researchers used in-vivo phage-display techniques to identify the peptide motif: CKGGRAKDC which preferentially homes to white-adipose vasculature. Its target was identified as prohibitin, which is present on vascular endothelial cells associated with white adipose tissue. Researchers then linked that targeting peptide to a mitochondrial-disrupting proapoptotic sequence. This created the compound later called: Adipotide.

What Are Researchers Studying?

Obesity

Obesity is the central application. In obese mice, targeted destruction of white-fat vasculature produced rapid loss of adipose tissue and normalization of several metabolic abnormalities. The strategy was then moved into spontaneously obese nonhuman primates, an important translational step because primate obesity more closely resembles human obesity than many engineered rodent models.

White adipose tissue

Adipotide isn't simply designed to “burn fat.” Its mechanism targets the vascular infrastructure supporting white adipose tissue. This is a fundamentally different strategy from: Semaglutide → appetite/metabolic signaling or: 5-Amino-1MQ → NNMT inhibition or: SLU-PP-332 → ERR-mediated oxidative metabolism. Adipotide attempts to make white-fat tissue regress by attacking its blood supply.

Prohibitin

Prohibitin is a multifunctional protein with roles in several cellular compartments. Researchers identified cell-surface prohibitin as a marker associated with white-adipose vasculature and used the CKGGRAKDC motif to target it. Subsequent research showed that prohibitin interacts with annexin A2 in adipose tissue and participates in fatty-acid transport biology, reinforcing that this isn't merely an arbitrary laboratory target. But prohibitin has functions beyond adipose tissue. That makes targeting specificity a major safety issue.

Insulin resistance

In obese rhesus monkeys, adipotide-associated fat loss was accompanied by improvements in insulin sensitivity. Researchers also observed reductions in: • Body weight • BMI • Abdominal circumference • Total body fat without evidence that the effect was simply explained by appetite suppression. These findings were one reason the primate study generated considerable excitement.

Visceral fat

MRI and DEXA measurements in obese monkeys confirmed reductions in adipose tissue rather than merely changes in water weight. Abdominal fat was reduced during treatment. This is much stronger evidence than simply weighing the animals. But it remains nonhuman primate evidence.

Targeted vascular therapy

Adipotide also serves as an interesting proof of concept for vascular targeting. The idea is: Different tissues can display distinctive molecules on their vascular surfaces. A targeting ligand can recognize those molecules. A therapeutic payload can then be delivered preferentially to that tissue. This approach originated partly from cancer-targeting research and was adapted to adipose tissue.

How Does It Work?

The simplified pathway: Adipotide ↓ CKGGRAKDC targeting motif recognizes prohibitin ↓ preferential binding to white-adipose vascular endothelium ↓ compound internalization ↓ D(KLAKLAK)₂ proapoptotic component disrupts mitochondrial membranes ↓ endothelial apoptosis ↓ loss of adipose vascular support ↓ white-adipose regression. This is not conventional lipolysis. It is targeted tissue ablation. That's a much more accurate description of why the compound is both scientifically interesting and potentially risky.

What Does the Research Show?

Human research

There is no established evidence that adipotide safely treats human obesity. The strongest translational efficacy evidence remains the nonhuman-primate study. The discovery that prohibitin-related targeting biology also exists in human white-fat vasculature provides mechanistic relevance, but it does not establish safety or efficacy of administering adipotide to people. So Aminodex should not describe it as: “a fat-loss peptide shown to work in humans.” It hasn't been.

Animal research

This is where adipotide's evidence becomes genuinely interesting. Mice Targeted adipose-vascular ablation caused substantial loss of white adipose tissue and reversed obesity-related metabolic abnormalities. Nonhuman primates In obese rhesus monkeys, treatment produced significant reductions in body weight and adiposity and improved insulin sensitivity. The primate step makes adipotide considerably more translationally developed than a compound supported only by mouse experiments. But it still isn't human clinical evidence.

In-vitro research

Mechanistic work has investigated: • Prohibitin binding • Endothelial targeting • Mitochondrial disruption • Apoptosis • Adipose-vascular biology • Prohibitin/annexin-A2 interactions These experiments help explain why adipotide can preferentially affect white-fat vasculature.

Notable Studies

Reversal of Obesity by Targeted Ablation of Adipose Tissue

animal

Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W · 2004

Researchers used in-vivo vascular targeting to identify CKGGRAKDC as a peptide motif that homes to white-adipose vasculature and associates with prohibitin. Linking the targeting sequence to a proapoptotic peptide selectively damaged adipose blood vessels, causing white-fat loss and rapid reversal of obesity-related metabolic abnormalities in mice.

Limitations: Mouse study. Targeted fat-tissue ablation in rodents does not establish human safety, durability, or clinical usefulness.

View publication →

A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys

animal

Barnhart KF, Christianson DR, Hanley PW, et al. · 2011

Researchers administered adipotide to spontaneously obese rhesus monkeys. Treatment reduced body weight, BMI, abdominal circumference and adipose tissue measured using imaging/body-composition methods and improved insulin resistance. Importantly, the study also identified predictable and reversible changes in renal proximal-tubule function across tested monkey species.

Limitations: Nonhuman-primate study with relatively small experimental groups. Renal effects create an important safety concern, and efficacy in monkeys does not establish an acceptable human risk-benefit profile.

View publication →

What We Still Don't Know

• Whether adipotide safely causes fat loss in humans • Safe human exposure • Human pharmacokinetics • Human biodistribution • Degree of kidney toxicity in humans • Whether renal effects remain reversible with repeated exposure • Long-term consequences of intentionally damaging adipose vasculature • Cardiovascular safety • Effects on normal adipose endocrine function • Effects on healthy versus dysfunctional fat depots • Effects on reproductive physiology • Long-term metabolic consequences • Whether weight returns after treatment • Whether vascular targeting remains selective in humans • Whether chronic exposure produces off-target tissue injury • Whether research-market adipotide matches material used in published studies

Related Compounds

Take the Adipotide research with you.

Get the Aminodex Adipotide Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.

One-time email. We do not add you to any mailing list.

Sources & References

Supplier Listings

A directory of relevant research suppliers for this compound is not yet available.